Finance

Lists
MRCK34:BVMF
Merck BDR
83,39 R$
0,00%
(0,00) 1D
24 шіл., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for MRCK34...
Open
83,72 R$
High
83,72 R$
Low
82,91 R$
Mkt. cap
323,72 млрд
Avg. vol.
2,19 мың
Volume
3,97 мың
52-wk high
84,81 R$
52-wk low
51,06 R$
Shares outstanding
2,47 млрд
No. of employees
74 мың
Open
83,72 R$
High
83,72 R$
Low
82,91 R$
Mkt. cap
323,72 млрд
Avg. vol.
2,19 мың
Volume
3,97 мың
52-wk high
84,81 R$
52-wk low
51,06 R$
Shares outstanding
2,47 млрд
No. of employees
74 мың
News stories
From sources across the web
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck BDR
CEORobert M Davis
Employees74 мың
Founded1891 ж. 01 қаң.
Headquarters-
SectorPharmaceutical industry
Websitemerck.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 ж. мау.
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
Revenue
15,81 млрд
17,28 млрд
16,40 млрд
16,29 млрд
Cost of goods sold
3,39 млрд
3,74 млрд
4,30 млрд
3,88 млрд
Cost of revenue
3,39 млрд
3,74 млрд
4,30 млрд
3,88 млрд
Research and development expenses
4,00 млрд
4,00 млрд
4,00 млрд
3,56 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,50 млрд
2,48 млрд
2,73 млрд
2,57 млрд
Operating expense
6,49 млрд
6,48 млрд
6,73 млрд
6,12 млрд
Total operating expenses
9,88 млрд
10,23 млрд
11,02 млрд
10,00 млрд
Operating income
5,92 млрд
7,05 млрд
5,38 млрд
6,29 млрд
Other non operating income
69,00 млн
-
41,00 млн
42,00 млн
EBT including unusual items
5,00 млрд
6,74 млрд
3,42 млрд
-3,53 млрд
EBT excluding unusual items
5,68 млрд
6,76 млрд
4,98 млрд
5,85 млрд
Income tax expense
571,00 млн
958,00 млн
458,00 млн
709,00 млн
Effective tax rate
11,42%
14,20%
13,39%
-20,06%
Other operating expenses
-
-
-
-
Net income
4,43 млрд
5,78 млрд
2,96 млрд
-4,24 млрд
Net profit margin
28,01%
33,49%
18,07%
-26,03%
Earnings per share
2,13
2,58
2,04
-1,28
Interest and investment income
69,00 млн
96,00 млн
69,00 млн
35,00 млн
Interest expense
-305,00 млн
-327,00 млн
-411,00 млн
-479,00 млн
Net interest expenses
-236,00 млн
-231,00 млн
-342,00 млн
-444,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
6,99 млрд
8,15 млрд
6,79 млрд
7,69 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer